Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Niccoli

Showing results (11-20 of 48) with videos related to

Pageof 5
Sort By:
The Journal of Rheumatology. Supplement|July 4, 2012
Infliximab in psoriatic arthritisFabrizio Cantini, Laura Niccoli, Carlotta Nannini, et al.
Expert Opinion on Drug Safety|June 20, 2020
Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus KinasesFabrizio Cantini, Corrado Blandizzi, Laura Niccoli, et al.
Biologics : Targets & Therapy|August 21, 2012
Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up studyFabrizio Cantini, Laura Niccoli, Emanuele Cassarà, et al.
Expert Review of Clinical Immunology|October 19, 2019
Biosimilars for the treatment of psoriatic arthritisFabrizio Cantini, Maurizio Benucci, Francesca Li Gobbi, et al.
Scandinavian Journal of Rheumatology|July 12, 2002
Renal cell carcinoma mimicking polymyalgia rheumatica. Clues for a correct diagnosisLaura Niccoli, Carlo Salvarani, Giovanna Baroncelli, et al.
International Journal of Rheumatic Diseases|January 5, 2011
Psoriatic arthritis: a systematic reviewFabrizio Cantini, Laura Niccoli, Carlotta Nannini, et al.
Expert Opinion on Drug Safety|December 23, 2021
Tailored first-line biologic and targeted synthetic disease modifying anti-rheumatic drugs therapy in patients with rheumatoid arthritis: 2021 updated ITABIO statementsFabrizio Cantini, Delia Goletti, Maurizio Benucci, et al.
Mediators of Inflammation|June 30, 2017
Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted BiologicsFabrizio Cantini, Carlotta Nannini, Laura Niccoli, et al.
BMC Musculoskeletal Disorders|June 15, 2015
Systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab: a case reportLaura Niccoli, Emanuele Cassarà, Olga Kaloudi, et al.
Expert Review of Anti-Infective Therapy|June 1, 2018
Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugsDelia Goletti, Linda Petrone, Giuseppe Ippolito, et al.
Pageof 5

Showing results (11-20 of 48) with videos related to

Sort By:
Pageof 5
The Journal of Rheumatology. Supplement|July 4, 2012
Infliximab in psoriatic arthritisFabrizio Cantini, Laura Niccoli, Carlotta Nannini, et al.
Expert Opinion on Drug Safety|June 20, 2020
Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus KinasesFabrizio Cantini, Corrado Blandizzi, Laura Niccoli, et al.
Biologics : Targets & Therapy|August 21, 2012
Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up studyFabrizio Cantini, Laura Niccoli, Emanuele Cassarà, et al.
Expert Review of Clinical Immunology|October 19, 2019
Biosimilars for the treatment of psoriatic arthritisFabrizio Cantini, Maurizio Benucci, Francesca Li Gobbi, et al.
Scandinavian Journal of Rheumatology|July 12, 2002
Renal cell carcinoma mimicking polymyalgia rheumatica. Clues for a correct diagnosisLaura Niccoli, Carlo Salvarani, Giovanna Baroncelli, et al.
International Journal of Rheumatic Diseases|January 5, 2011
Psoriatic arthritis: a systematic reviewFabrizio Cantini, Laura Niccoli, Carlotta Nannini, et al.
Expert Opinion on Drug Safety|December 23, 2021
Tailored first-line biologic and targeted synthetic disease modifying anti-rheumatic drugs therapy in patients with rheumatoid arthritis: 2021 updated ITABIO statementsFabrizio Cantini, Delia Goletti, Maurizio Benucci, et al.
Mediators of Inflammation|June 30, 2017
Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted BiologicsFabrizio Cantini, Carlotta Nannini, Laura Niccoli, et al.
BMC Musculoskeletal Disorders|June 15, 2015
Systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab: a case reportLaura Niccoli, Emanuele Cassarà, Olga Kaloudi, et al.
Expert Review of Anti-Infective Therapy|June 1, 2018
Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugsDelia Goletti, Linda Petrone, Giuseppe Ippolito, et al.
Pageof 5